Kinetic characterization of a novel endo- β -N-acetylglucosaminidase on concentrated bovine colostrum whey to release bioactive glycans

Sercan Karav¹, Annabelle Le Parc¹, Juliana Maria Leite Nobrega de Moura Bell¹, Camille Rouquié¹, David A. Mills^{1,2,3}, Daniela Barile^{1,2} and David E. Block^{3,4}

¹Department of Food Science and Technology, University of California, One Shields Avenue, Davis, CA 95616, USA

²Foods for Health Institute, University of California, One Shields Avenue, Davis, CA 95616, USA

³Department of Viticulture and Enology, University of California, Davis, CA, USA

⁴Department of Chemical Engineering and Materials Science, University of California, Davis, CA, USA

Correspondence: David E. Block

E-mail: deblock@ucdavis.edu

Abstract

EndoBI-1 is a recently isolated endo- β -*N*-acetylglucosaminidase, which cleaves the *N*-*N*'-diacetyl chitobiose moiety found in the *N*-glycan core of high mannose, hybrid and complex *N*-glycans. These *N*-glycans have selective prebiotic activity for a key infant gut microbe, *Bifidobacterium longum* subsp. *infantis*. The broad specificity of EndoBI-1 suggests the enzyme may be useful for many applications, particularly for deglycosylating milk glycoproteins in dairy processing. To facilitate its commercial use, we determined kinetic parameters for EndoBI-1 on the model substrates ribonuclease B and bovine lactoferrin, as well as on concentrated bovine colostrum whey. K_m values ranging from 0.25-0.49, 0.43-1.00 and 0.90-3.18 mg/mL and V_{max} values ranging from 3.5×10^{-3} - 5.09×10^{-3} , 4.5×10^{-3} - 7.75×10^{-3} and 1.9×10^{-2} - 5.2×10^{-2} mg/mL*min were determined for ribonuclease B, lactoferrin and whey, respectively. In general, EndoBI-1 showed the highest apparent affinity for ribonuclease B, while the maximum reaction rate was the highest for concentrated whey. EndoBI-1-released *N*-glycans were quantified by a phenol-sulphuric total carbohydrate assay and the resultant *N*-glycan structures monitored by Nano-LC-Chip-Q-TOF MS. The kinetic parameters and structural characterization of glycans released suggest EndoBI-1 can facilitate large-scale release of complex, bioactive glycans from a variety of glycoprotein substrates. Moreover, these results suggest that whey, often considered as a waste product, can be used effectively as a source of prebiotic *N*-glycans.

Keywords: Deglycosylation, *N*-glycans, Endo- β -*N*-acetylglucosaminidase

1. Introduction

Glycosylation of human and bovine milk proteins is a post-translational modification that results from enzymatic processing of polypeptide chains in mammary epithelial cells. Protein glycosylation influences the biological and physicochemical properties of the protein including targeting, folding and stability [1]. Glycans are linked to proteins through *O*-glycosidic or *N*-glycosidic bonds. *O*-linked glycans (*O*-glycans) are frequently attached to the polypeptide via *N*-acetylgalactosamine to a hydroxyl group of a serine or threonine residue, and can be extended into a variety of different structural core classes. *N*-linked glycans (*N*-glycans) are linked via *N*-acetylglucosamines (HexNAc) to an asparagine residue of proteins in the specific amino acid sequence AsN-X-Ser/Thr (where X can be any amino acid except proline) [2].

Human milk oligosaccharides (HMO) are known to guide the development of the infant intestinal microbiota, in particular enriching a beneficial bifidobacterial population [3, 4], which has recently been implicated in a range of health benefits including anti-adhesive antimicrobial activity, positive modulation of intestinal epithelial cell responses, immune modulation, protection against necrotizing enterocolitis and stimulation of brain development [5-9]. Unfortunately, many infants do not have access to human milk and, consequently, there have been numerous efforts to identify functionally equivalent molecules for infant formula and other prebiotic, therapeutic uses. Bovine milk represents one possible source of structurally similar oligosaccharides [10], however the concentration of these oligosaccharides in fluid milk is 20-fold lower than HMOs in human milk—a fact that limits their usage commercially [11, 12]. Alternatively, bovine milk glyco-conjugates such as glycoproteins might be considered as an additional source

of bovine glycans with desirable bioactivities. In fact, we have recently shown that a key infant gut microbe, *Bifidobacterium longum* subsp. *infantis*, consumes these conjugated *N*-glycans as a carbon source while other less desirable microbes do not (unpublished results). Whey, a by-product of cheese-making, contains ~4.5 g of glycoproteins per L [13]. Because only half of the total whey (190,000,000 ton/year) is currently utilized by the food industry, it is still considered a waste product [14]. Therefore, the use of whey as a source of bioactive glycans may also improve the sustainability of the dairy industry. However, robust enzymes with the appropriate activity to release the conjugated glycans are necessary for this process to become a commercial reality.

Peptidyl-*N*-glycosidases (PNGases) are widely used for deglycosylation of glycoproteins for analytical research purposes [15]. A PNGase (peptide- N^4 - (N-acetyl- β -glucosaminyl), glycopeptidase, N-glycanase, glycoaminidase or N-glycosidase) cleaves asparagine-linked oligosaccharides from glycoproteins by hydrolyzing the amide side chain [16, 17]. Commercially available PNGases (PNGase A from sweet almond and PNGase F from *Falvobacterium meningosepticum*) release several kinds of *N*-linked glycans irrespective of their size or charge [18-20]. However, if fucose is α 1,3-linked to *N*-acetylglucosamine, the *N*-glycans are resistant to hydrolysis by PNGase F [21]. We recently showed that an endo- β -*N*-acetylglucosaminidase (EndoBI-1) isolated from *Bifidobacterium longum* subsp. *infantis* ATCC 15697 has the ability to cleave the *N*-*N'*-diacetyl chitobiose moiety found in the *N*-glycan core of high mannose, hybrid and complex *N*-glycans [1]. EndoBI-1 activity is not affected by fucosylation of the *N*-glycan core, and it is heat resistant making it attractive for use in various industrial processes.

Despite the wide potential use of this enzyme, data are not yet available on its kinetics and substrate specificity in terms of initial maximum rates and K_m -values.

In this study, we examine the kinetic parameters of EndoBI-1 for three purified, glycosylated substrates: model proteins ribonuclease B (RNase B) and bovine milk lactoferrin (bLF), as well as bovine colostrum whey protein concentrate. A goal was to investigate the potential use of EndoBI-1 for large-scale *N*-glycan production of released glycans from whey. Different direct and linearized plotting methods [22-24] were used to facilitate the prediction of kinetics parameters of the EndoBI-1. The values obtained enable comparison to other enzymes and estimations of optimal combinations of enzyme concentration and incubation time to yield complete *N*-glycan release from whey at a commercial-scale. These well determined kinetic parameters will enable us to produce a new prebiotic source efficiently. Finally, the structures of the released *N*-glycans were elucidated for each substrate by advanced mass spectrometry methods.

2. Materials Methods

2.1 Gene Cloning, expression and purification

A pEcoTM-T7-cHis, Eco Cloning Kit (GeneTarget Inc, San Diego, CA, USA) was used for gene cloning. The EndoBI-1 coding sequence was amplified from *B. longum* subsp. *infantis* ATCC 15697 genomic DNA with primers; 5'-TTTGTACAAAAAGCAGGCACCATGAATGCGGACGCCGTTTCTCCGAC-3' and 5'-TTTGTACAAGAAAGCTGGGTGCGCGTTCGCACTCAGTTGCTTCGG-3' and then cloned into the pEco-T7-cHis vector. The vector was transformed into *E. coli* Dh5 α and *E. coli* BL21* for protein expression. The sequence was confirmed (IC-1006-

forward; TAATACGACTCACTATAGG, IC-1006-reverse;
TGCTAGTTATTGCTCAGCGG). Poly-histidine-tagged EndoBI-1 was produced in the
E. coli host with a yield of ~1.7 mg/L on LB media under optimal induction conditions
(0.5 mM IPTG, 37 °C for 4 hours). The protein was purified following bacterial lysis
using affinity chromatography with 5 mL prepacked Ni-charged columns (Bio-Rad,
Hercules, CA, USA). The bound protein was eluted with 80 mM imidazole with high
purity (data not shown).

2.2 Substrates

The concentration of bovine colostrum whey proteins was carried out using a
pilot-scale cross-flow membrane system (Model L, GEA Filtration, Hudson, WI, USA).
The system was composed of a 6.4 cm diameter spiral membrane housing (1-2 m² area), a
95 L jacketed stainless steel hold tank, a Proline Promass 80 E flow-meter
(Endress+Hauser, Reinach, Switzerland), a heat exchanger, and a 7.0 HP feed pump
(Hydra-Cell™ Pump, model D10EKSGSNECF, Minneapolis, MN, USA). After
upstream lactose hydrolysis (0.1% lactase, 30 min, 40-43°C), seventy-four liters of
bovine colostrum whey were ultrafiltered using this system in single batch with a 10 kDa
molecular weight cut-off polyethersulfone spiral-wound membrane (effective area of 1.86
m²) up to a 5.4 concentration factor (concentration factor = volume of feed/volume of
retentate). Whey protein concentration was performed at 40-43°C with a transmembrane
pressure of 3.0 bars and a recirculation flow rate of 10 L/min. After a concentration factor
of 5.4 was achieved, the protein-rich retentate was diluted back to its original volume
with water. Two diafiltrations were performed to increase the removal of

monosaccharides and oligosaccharides from the ultrafiltration retentate. RNase B from bovine pancreas and bLF were obtained from Sigma-Aldrich (St. Louis, MO, USA). To directly compare the pure glycoproteins (bLF and RNase B) to concentrated whey protein, five times the whey protein mass was used in reactions, to account for the mixed population of glycosylated (20%) and un-glycosylated (80%) proteins in whey [13, 25].

2.3 Glycoprotein digestion by EndoBI-1 and glycan quantification

Enzyme and substrate concentration were determined by a Qubit Protein Assay Kit (Life Technologies, Grand Island, NY, USA). RNase B, bLF and concentrated bovine whey (0.1-0.8 mg/mL) were incubated for various times from 0 to 45 min at 37 °C with 0.025 mg/ml EndoBI-1 in a 0.02 M Na₂HPO₄ buffer solution at pH 5. The reactions were terminated by the addition of 1M Na₂CO₃. Protein precipitation was carried out using a ratio of 4:1 cold pure ethanol added into the samples to precipitate proteins and collect the released *N*-glycans. Samples were dried overnight by vacuum centrifugation and were rehydrated in 100 µL of water, vortexed and sonicated. All experiments were performed in at least triplicate. A Carbohydrate Assay Kit, from Biovision, (Milpitas, CA, USA), was used to quantify released *N*-glycans with mannose as a standard. Aliquots of 30 µl of sample and 150 µl of concentrated sulfuric acid (98%) were added to each well. Samples were mixed on a shaker for ~1 min and incubated at 85°C for 15 min. After incubation, 30 µl of developer (provided by Biovision) were added to each well. Samples were mixed on the shaker for 5 min and the OD of each sample was measured at 490 nm. Sample OD was converted to carbohydrate concentration using a mannose standard curve linear function.

2.4 Determination of kinetic constants

Because of the complex nature of glycosylated and non-glycosylated proteins in whey, we first tested the activity of the EndoBI-1 on the purified model glycoproteins RNaseB and Lactoferrin. This allowed us to calculate kinetic parameters that could be compared to those for the more complex substrate found in whey, as well as identify a concentration range for the whey protein that would facilitate measurement of kinetic parameters and the heterogeneous structures of glycans released.

In this manner, RNase B, bLF and bovine whey concentrate with initial concentrations ranging from 0.1 to 0.8 mg/mL were chosen to determine the reaction curves for a total time of 45 min. The initial rate of reaction was obtained from the slopes calculated from samples taken in the first 20 min of reaction for each of the three substrates. Kinetic values (K_m and V_{max}) were determined from the initial rates at various initial substrate concentrations by using Graph Prism 6.0 software with non-linear and linearized plotting techniques including Lineweaver-Burk, Hanes-Woolf and Eadie-Hofstie [22, 23, 26].

2.5 Glycan purification for Nano-LC-Chip-Q-TOF MS

After enzymatic digestion and protein precipitation by ethanol, 100 μ L of samples in water were loaded in duplicate on PGC SPE plates (Glygen, Columbia, MD, USA) that were conditioned using 3 x 100 μ L of 80% ACN containing 0.1% TFA in water, followed by 3 x 100 μ L of water. After sample loading, wells were washed using 6 $\times$ 200 μ L of water and *N*-glycans were eluted using 3 $\times$ 200 μ L of 40% ACN containing 0.1% TFA in water. The enriched *N*-glycans fractions were dried overnight in vacuum.

Samples were rehydrated in 50 μ L of water, vortexed, sonicated and diluted 50 times prior to mass spectrometry analysis. For each sample, duplicates were analyzed by mass spectrometry.

2.6 Nano-LC-Chip-Q-TOF Mass spectrometry analysis

N-glycans were analyzed using the Agilent 6520 accurate-mass Q-TOF-LC/MS with a microfluidic nano-electrospray chip (Agilent Technologies, Santa Clara, CA, USA). *N*-glycans were separated using an HPLC-chip with a 40-nL enrichment column and a 43-mm x 75- μ m analytical column, both packed with 5 μ m porous graphitized carbon (PGC). The system was composed of a capillary and nanoflow pump, and both used binary solvents consisting of solvent A (3% ACN, 0.1% formic acid in water (v/v)) and solvent B (90% ACN, 0.1% formic acid in water (v/v)). Two microliters of sample were loaded with solvent A at a capillary pump flow rate of 4 μ L/min. *N*-glycan separation was performed on a 65-min gradient delivered by the nanopump at a flow rate of 0.3 μ L/min. The 65-min gradient followed this program: 0% B (0.0–2.5 min), 0 to 16% B (2.5–20.0 min), 16 to 44% B (20.0–30.0 min), 44 to 100% B (30.0–35.0 min) and 100% B (35.0–45.0 min). The gradient was followed by equilibration at 0% B (45.0–65.0 min). Data were acquired within the mass range of 450–3000 m/z for *N*-glycans in the positive ionization mode with an acquisition rate of 1 spectra/s. An internal calibrant ion of 922.010 m/z from the tuning mix (ESI-TOF Tuning Mix G1969–85000, Agilent Technologies) was used for continual mass calibration. For tandem MS analysis, *N*-glycans were fragmented with nitrogen as the collision gas. Spectra were acquired within the mass range of 100–3000 m/z . The collision energies correspond to voltages

(Vcollision) that were based on the equation: $V_{\text{collision}} = m/z (1.5/100 \text{ Da}) \text{ Volts} - 3.6$ Volts; where the slope and offset of the voltages were set at (1.5/100 Da) and (-3.6) respectively. Data acquisition was controlled by MassHunter Workstation Data Acquisition software (Agilent Technologies).

2.7 *N*-glycan identification

Compounds were identified using MassHunter Qualitative Analysis software (version B.06.00 SP2, Agilent Technologies) and the Find by Formula algorithm. The compounds were matched to a bovine milk *N*-glycan library using a mass error tolerance of 20 ppm [27]. The *N*-glycans from the library were composed of hexose (Hex), HexNAc, fucose, *N*-acetylneuraminic acid (NeuAc) and *N*-glycolylneuraminic acid (NeuGc). For compound identification, a minimum abundance of 1000 counts was used to filter out low-abundance compounds. Identified compounds were extracted allowing charge states of +1 to +3 and the isotope model was “glycans.” Extracted ion chromatogram peaks were smoothed with the Gaussian function, and the resulting peaks were integrated via the “agile” algorithm. The assignment of *N*-glycans was confirmed by tandem mass spectrometry.

3. Results

3.1 EndoBI-1 production and confirmation of its activity on RNase B

The activity of recombinant EndoB-1 was tested on model glycoprotein RNase B that contains only high mannose *N*-linked glycans. RNase B is a 17 kDa *N*-glycosylated

protein and its deglycosylation results in a 14-15 kDa deglycosylated protein. Confirmation of the deglycosylation activity of RNase B by purified EndoB-1 and a control commercial enzyme PNGase F are shown in Figure 1. Because EndoBI-1 cleaves one HexNAc residue less than PNGase F, the molecular weight of deglycosylated RNase B is slightly higher than 14 kDa for the EndoBI-1 enzyme. Substrates were denatured at 95 °C for 5 min in a final concentration of 10 mM DTT prior to the hydrolysis.

3.2 Determination of K_m and V_{max} by non-linear and linearized plotting

Using the Michaelis-Menten model, the velocity of the reaction is obtained from the initial linear decrease of the substrate concentration or the increase in product concentration. K_m , the substrate concentration when the reaction reaches half of V_{max} , can also be calculated from the obtained curve [28]. The direct plot may be obtained by plotting the initial reaction rate (v) against the corresponding initial substrate concentration (S) that yields a hyperbolic curve of saturation. However, it may be difficult to locate the asymptotes properly or potential deviations from the expected curve may be difficult to monitor. Thus, there are several linearized plotting methods that have been developed including Lineweaver-Burk, Hanes-Woolf and Eadie-Hofstman, each with their own advantages and disadvantages [22-24, 29].

The kinetics of EndoBI-1 deglycosylating RNase B, bLF and whey glycoproteins were determined using various initial concentrations of each substrate over 45 min for each reaction (Figure 2). The reaction rate for each substrate was constant (i.e. slope of concentration versus time was constant) for the first 20 min, and initial rates of reaction

were therefore calculated from the slopes of these data. The assumption of $[S] \gg [E]$ is not valid after 20 minutes. Therefore, the enzyme concentration becomes limited and reaction rate gets slower.

The direct plot was created by plotting the reaction rate (v) against the initial substrate concentration (S). These plots all resulted in a hyperbolic or saturation relationship (Figure 3). K_m values of 0.25, 0.43 and 0.90 mg/mL and V_{max} values of 5.09×10^{-3} , 7.75×10^{-3} and 5.2×10^{-2} mg/mL*min were calculated for RNase B, bLF and bovine whey, respectively. The linearization methods, Lineweaver-Burk ($1/S$ vs $1/v$), Hanes-Woolf (S vs S/v) and Eadie-Hofstee (v/S vs. v), plotting techniques were also used (Figure 4) to estimate the kinetic parameters for each substrate. K_m and V_{max} values estimated from these plotting techniques and a comparison with the non-linear curve fitting is shown in Table 1. In general, there is a significant difference in the parameters derived from the non-linear and linearized fitting techniques for each substrate. It was shown that K_m values estimated from non-linear fitting are 1.77, 2 and 2.92 fold lower than the average of the three linearized fitting methods for RNase B, bLF and bovine whey, respectively, though the general trends are the same. K_m refers to the minimum substrate concentration that achieves half of V_{max} . Thus, the results demonstrate that the enzyme has a higher apparent affinity for RNase B than for the other substrates. V_{max} values ranging from 3.5×10^{-3} - 5.09×10^{-3} , 4.5×10^{-3} - 7.75×10^{-3} and 1.9×10^{-2} - 5.2×10^{-2} mg/mL*min were found for RNase B, bLF and bovine whey, respectively. These results indicate that the maximum rate of reaction is higher with the concentrated bovine colostrum whey as substrate compared with the model glycoprotein substrates and that the concentrated whey prepared at the UC Davis Milk Processing Lab can be used as *N*-

glycan source at a rate of 2.08 mg N-glycan/ml*min per 1 mg/ml EndoBI-1 under optimal conditions.

3.3 *N*-Glycan structures

Mass Spectrometry analysis of released *N*-glycan from RNase B, bLF and bovine colostrum whey protein concentrate after digestion by EndoBI-1 provides information on the glycosylation patterns for the three substrates as well as their potential bioactivity. Application of the bovine milk *N*-glycan library as a mass filter in Find by Formula allowed the identification of *N*-glycan compositions with high mass accuracy and retention time reproducibility [27]. Tandem MS analysis generated specific fragment ions that were common to all *N*-glycans allowing the confirmation of 5, 33 and 18 different oligosaccharide structures for RNase B, bLF and bovine colostrum whey protein concentrate, respectively. The details of all structures, including neutral and sialylated *N*-glycans, are described in the supporting information, (Table S1, S2 and S3).

RNase B is a well-characterized bovine glycoprotein that contains high mannose glycans with five to nine mannoses. Nano-LC-Chip-Q-TOF MS confirmed the presence of only high mannose *N*-glycans that are eluted between 11 and 17 min and are linked to the unique *N*-glycosylation site of the protein, ⁶⁰Asn [30]. The spectrum shown in Figure 5 illustrates the fragment pattern of a high mannose *N*-glycan with 1032.36 m/z, *z*=1. The spectrum shows a 162 Da difference between each peak that corresponds to the molecular weight of a mannose residue. Different high mannose isomers were resolved by nano-LC-Chip-Q-TOF MS for RNase B.

Figure 6 presents extracted compound chromatograms (ECCs) of bLF and bovine colostrum whey protein concentrate. Glycomics profiling demonstrates different patterns for these two substrates. Whey glycoproteins and pure bLF exhibit high-mannose *N*-glycans and complex/hybrid *N*-glycans, including fucosylated and sialylated *N*-glycans.

4. Discussion

In the present study, we characterize the kinetics of glycan release from model glycoproteins using a novel endo- β -*N*-acetylglucosaminidase, EndoBI-1, obtained from *B. longum subsp. infantis* ATCC 15697. Importantly, we also evaluated the ability of this enzyme to catalyze the conversion of a dairy waste stream, concentrated bovine colostrum whey prepared at the pilot-scale (UC Davis Milk Processing Lab), into a potential bioactive *N*-glycan source. Using this enzyme, we demonstrated *N*-glycan release from glycoproteins in whey with a maximum rate of 5.2×10^{-2} mg/mL min using 0.025 mg enzyme/mL.

We first showed that *N*-glycans are, in fact, released from both the purified model glycoproteins and the bovine colostrum whey protein concentrate using this novel enzyme. This demonstrates that the EndoBI-1 enzyme has the potential to release bioactive glycans from bovine-milk-related glycoproteins. A wider variety of *N*-glycans, including anomers and isomers, was released from pure bLF than from glycoproteins in bovine colostrum whey protein concentrate. This difference can be explained by the fact that whey is a complex fluid that contains *N*-linked as well as *O*-linked and nonglycosylated proteins, including β -lactoglobulin, α -lactalbumin, serum albumin bovine immunoglobulin and lactoferrin. Among these proteins, lactoferrin and

immunoglobulins are some of the most abundant glycoproteins in bovine milk. [25, 31]. Non-glycosylated whey proteins, including α -lactalbumin (1.2 g/L) and β -lactoglobulin (3.2 g/L), are present at higher concentration than whey *N*-linked proteins like lactoferrin and immunoglobulins, [32]. These differences could explain why the *N*-glycan release by EndoBI-1 is more efficient on a pure glycoprotein than a complex mixture that contains lower relative amount of glycoproteins. It should be noted, however, that structure determinations were made using samples taken early on in the reaction corresponding to when the reactions were still at their initial rate. It is possible that samples taken at a later stage of the reactions could yield a different distribution of released glycans.

To further characterize the reaction kinetics of EndoBI-1, we calculated the Michaelis-Menten kinetic parameters, V_{max} and K_m for two purified glycoprotein substrates and bovine colostrum whey protein concentrate, an example of a potential commercial substrate for this novel enzyme. Interestingly, there are significant differences in the kinetic parameters derived from different fitting techniques for each substrate. These results are consistent with other studies that compared the non-linear and linearized plotting techniques [33-35]. In general, non-linear plotting resulted in the underestimation of the kinetic parameters compared to the linearized methods. It is possible that more sophisticated methods for non-linear fitting [36] would improve the agreement between methods. However, the general trends in kinetic parameters for the three substrates are, in themselves, instructive and consistent between methods.

The lowest K_m was observed for RNase B while the highest K_m value was determined for whey. The lower apparent affinity of the enzyme for whey glycoproteins is explained by the heterologous nature of the substrate as described above. Because

whey includes not only glycoproteins but also non-glycosylated proteins, this may result in the overestimation of the K_m value, or may also be a good indicator of the competitive inhibition that might be expected by non-substrate glycoproteins and non-glycosylated proteins [37, 38].

Although, RNase B showed the highest enzyme-protein affinity, it has the lowest V_{max} value compared to bLF and whey-derived glycoproteins. RNase B has a single high mannose *N*-glycosylation site that might result in low *N*-glycan release efficiency per amount of a given protein. While EndoBI-1 showed lower affinity for bLF than RNase B, it has a slightly higher V_{max} for bLF than for RNase B. This might be the result of the multiple and more complex *N*-glycan content of bLF. The highest V_{max} value was observed for whey. The enzyme exhibited a 5-10 fold higher V_{max} on bovine colostrum whey protein concentrate than on RNase B and bLF depending on the fitting method used to calculate this parameter. Although, EndoBI-1 has *lower apparent affinity* value for whey glycoproteins, its high maximum reaction rate could be a result of a high biantennary *N*-glycan content of whey immunoglobulins. Immunoglobulins mainly contain biantennary *N*-glycans, while the model proteins we used contain mostly tri- and tetra-antennary-type *N*-glycans (Fig. 6) Because most of endo- β -*N*-acetylglucosaminidases prefer the high mannose and biantennary *N*-glycans to tri- and tetra-antennary-type *N*-glycans, EndoBI-1 digests the *N*-glycans of immunoglobulin efficiently, which results in a higher observed activity on whey.

The kinetic parameters of PNGase F for various glycoproteins have been investigated by several groups [15, 39, 40]. In general, it was reported that the denaturation of glycoproteins is essential for PNGase F activity. The K_m values of

PNGase F for denatured glycoproteins are higher than EndoBI-1 values that we determined in this study. Moreover, lower V_{max} values observed in these studies compared to our findings indicate that EndoBI-1 is an efficient alternative enzyme that can be used for large-scale glycan production. The low V_{max} of PNGase F can be explained by its limited activity on core fucosylated *N*-glycans.

Successful release of these *N*-glycans from bovine milk glycoproteins, which were recently shown to be a new prebiotic source (submitted), by EndoBI-1, an enzyme active on all *N*-glycan cores, will enable further investigation of the biological and potential nutritional or therapeutic functions of bioactive glycans in bovine milk streams and lead to their larger-scale commercialization. However, a necessary step in this process is to fully characterize the enzymatic behavior and kinetics of the enzyme on a number of food substrates, including various dairy streams. Moreover, the use of these enzymes to release bioactive glycans from dairy processing waste streams like whey would also make dairy processing more economically and environmentally sustainable.

Acknowledgements

This work has been supported by University of California Discovery Grant Program, the UC Davis RISE program, the Bill and Melinda Gates Foundation, National Institutes of Health awards R21AT006180, R01AT007079 and the Peter J. Shields Endowed Chair in Dairy Food Science.

5. References

1. Garrido, D., et al., *Endo-beta-N-acetylglucosaminidases from infant gut-associated bifidobacteria release complex N-glycans from human milk glycoproteins*. Molecular & cellular proteomics : MCP, 2012. **11**(9): p. 775-85.
2. Legrand, D., et al., *Lactoferrin: a modulator of immune and inflammatory responses*. Cellular and molecular life sciences : CMLS, 2005. **62**(22): p. 2549-59.
3. Sela, D.A. and D.A. Mills, *The marriage of nutrigenomics with the microbiome: the case of infant-associated bifidobacteria and milk*. The American journal of clinical nutrition, 2014. **99**(3): p. 697S-703S.
4. Zivkovic, A., et al., *Establishment of a milk-oriented microbiota (MOM) in early life: how babies meet their MOMs*. Funct Foods Rev, 2013. **15**: p. 3-12.
5. Kunz, C., et al., *Oligosaccharides in human milk: structural, functional, and metabolic aspects*. Annual review of nutrition, 2000. **20**(1): p. 699-722.
6. Newburg, D.S., G.M. Ruiz-Palacios, and A.L. Morrow, *Human milk glycans protect infants against enteric pathogens*. Annu. Rev. Nutr., 2005. **25**: p. 37-58.
7. Rudloff, S., et al., *Urinary excretion of lactose and oligosaccharides in preterm infants fed human milk or infant formula*. Acta Paediatrica, 1996. **85**(5): p. 598-603.
8. Patel, B.K. and J.S. Shah, *Necrotizing enterocolitis in very low birth weight infants: a systemic review*. ISRN gastroenterology, 2012. **2012**.
9. Lucas, A., et al., *Breast milk and subsequent intelligence quotient in children born preterm*. The Lancet, 1992. **339**(8788): p. 261-264.
10. Zivkovic, A.M. and D. Barile, *Bovine milk as a source of functional oligosaccharides for improving human health*. Advances in nutrition, 2011. **2**(3): p. 284-9.
11. Tao, N., et al., *Bovine milk glycome*. Journal of dairy science, 2008. **91**(10): p. 3768-78.
12. Tao, N., et al., *Variations in bovine milk oligosaccharides during early and middle lactation stages analyzed by high-performance liquid chromatography-chip/mass spectrometry*. Journal of dairy science, 2009. **92**(7): p. 2991-3001.
13. de Wit, J.N., *Marschall Rhone-Poulenc Award Lecture. Nutritional and functional characteristics of whey proteins in food products*. Journal of dairy science, 1998. **81**(3): p. 597-608.
14. Galvao, C.M., et al., *Controlled hydrolysis of cheese whey proteins using trypsin and alpha-chymotrypsin*. Applied biochemistry and biotechnology, 2001. **91-93**: p. 761-76.
15. Altmann, F., S. Schweiszer, and C. Weber, *Kinetic comparison of peptide: N-glycosidases F and A reveals several differences in substrate specificity*. Glycoconjugate Journal, 1995. **12**(1): p. 84-93.
16. Nuck, R., et al., *Optimized deglycosylation of glycoproteins by peptide-N4-(N-acetyl-beta-glucosaminyl)-asparagine amidase from Flavobacterium meningosepticum*. Glycoconjugate journal, 1990. **7**(4): p. 279-86.

- 440 17. Takahashi, N., *Demonstration of a new amidase acting on glycopeptides.*
441 Biochemical and biophysical research communications, 1977. **76**(4): p. 1194-
442 201.
- 443 18. O'Neill, R.A., *Enzymatic release of oligosaccharides from glycoproteins for*
444 *chromatographic and electrophoretic analysis.* Journal of chromatography. A,
445 1996. **720**(1-2): p. 201-15.
- 446 19. Szabo, Z., A. Guttman, and B.L. Karger, *Rapid release of N-linked glycans from*
447 *glycoproteins by pressure-cycling technology.* Analytical chemistry, 2010.
448 **82**(6): p. 2588-93.
- 449 20. Morelle, W., et al., *Analysis of N- and O-linked glycans from glycoproteins using*
450 *MALDI-TOF mass spectrometry.* Methods in molecular biology, 2009. **534**: p.
451 5-21.
- 452 21. Tretter, V., F. Altmann, and L. Marz, *Peptide-N4-(N-acetyl-beta-*
453 *glucosaminyl)asparagine amidase F cannot release glycans with fucose*
454 *attached alpha 1---3 to the asparagine-linked N-acetylglucosamine residue.*
455 *European journal of biochemistry / FEBS*, 1991. **199**(3): p. 647-52.
- 456 22. Woolf, B., *The addition compound theory of enzyme action.* The Biochemical
457 journal, 1931. **25**(1): p. 342-8.
- 458 23. Hanes, C.S., *Studies on plant amylases: The effect of starch concentration upon*
459 *the velocity of hydrolysis by the amylase of germinated barley.* The Biochemical
460 journal, 1932. **26**(5): p. 1406-21.
- 461 24. Tummler, K., et al., *New types of experimental data shape the use of enzyme*
462 *kinetics for dynamic network modeling.* The FEBS journal, 2014. **281**(2): p.
463 549-71.
- 464 25. Madureira, A.R., et al., *Bovine whey proteins – Overview on their main*
465 *biological properties.* Food Research International, 2007. **40**(10): p. 1197-
466 1211.
- 467 26. Burk, D., H. Lineweaver, and C.K. Horner, *The Specific Influence of Acidity on*
468 *the Mechanism of Nitrogen Fixation by Azotobacter.* Journal of bacteriology,
469 1934. **27**(4): p. 325-40.
- 470 27. Nwosu, C.C., et al., *Comparison of the human and bovine milk N-glycome via*
471 *high-performance microfluidic chip liquid chromatography and tandem mass*
472 *spectrometry.* Journal of proteome research, 2012. **11**(5): p. 2912-24.
- 473 28. Michaelis, L., et al., *The original Michaelis constant: translation of the 1913*
474 *Michaelis-Menten paper.* Biochemistry, 2011. **50**(39): p. 8264-9.
- 475 29. Dowd, J.E. and D.S. Riggs, *A Comparison of Estimates of Michaelis-Menten*
476 *Kinetic Constants from Various Linear Transformations.* The Journal of
477 biological chemistry, 1965. **240**: p. 863-9.
- 478 30. An, H.J., et al., *Determination of N-Glycosylation Sites and Site Heterogeneity in*
479 *Glycoproteins.* Analytical Chemistry, 2003. **75**(20): p. 5628-5637.
- 480 31. Sánchez, L., et al., *Concentration of lactoferrin and transferrin throughout*
481 *lactation in cow's colostrum and milk.* Biological Chemistry Hoppe-Seyler,
482 1988. **369**(9): p. 1005-1008.
- 483 32. De Wit, J.N., *Nutritional and functional characteristics of whey proteins in food*
484 *products.* Journal of Dairy Science, 1998. **81**(3): p. 597-608.

- 485 33. Ritchie, R.J. and T. Prvan, *Current statistical methods for estimating the K-m*
486 *and V-max of Michaelis-Menten kinetics*. Biochemical Education, 1996. **24**(4):
487 p. 196-206.
- 488 34. Kadam, R.S. and K.R. Iyer, *Isolation of Liver Aldehyde Oxidase Containing*
489 *Fractions from Different Animals and Determination of Kinetic Parameters for*
490 *Benzaldehyde*. Indian Journal of Pharmaceutical Sciences, 2008. **70**(1): p. 85-
491 U1.
- 492 35. Tummler, K., et al., *New types of experimental data shape the use of enzyme*
493 *kinetics for dynamic network modeling*. Febs Journal, 2014. **281**(2): p. 549-
494 571.
- 495 36. Coleman, M.C. and D.E. Block, *Nonlinear experimental design using Bayesian*
496 *regularized neural networks*. Aiche Journal, 2007. **53**(6): p. 1496-1509.
- 497 37. Ascenzi, P., M.G. Ascenzi, and G. Amiconi, *Enzyme Competitive-Inhibition -*
498 *Graphical Determination of Ki and Presentation of Data in Comparative-*
499 *Studies*. Biochemical Education, 1987. **15**(3): p. 134-135.
- 500 38. Lizama, H.M. and I. Suzuki, *Synergistic Competitive-Inhibition of Ferrous Iron*
501 *Oxidation by Thiobacillus-Ferrooxidans by Increasing Concentrations of Ferric*
502 *Iron and Cells*. Applied and Environmental Microbiology, 1989. **55**(10): p.
503 2588-2591.
- 504 39. Lee, K.B., et al., *A new approach to assay endo-type carbohydrases:*
505 *bifluorescent-labeled substrates for glycoamidases and ceramide glycanases*.
506 Analytical Biochemistry, 1995. **230**(1): p. 31-36.
- 507 40. Mussar, K.J., et al., *Peptide: N-glycosidase F: studies on the glycoprotein*
508 *aminoglycan amidase from* *Flavobacterium meningosepticum**.* Journal
509 of biochemical and biophysical methods, 1989. **20**(1): p. 53-68.

Table I. Summary of the regressions shown in fig. 3&4 (linearized equations, quantities plotted on the *x* and *y* axis and results for *v* in mg/mL*min and *K_m* in mg/ml.).

	Non-linearized plotting	Lineweaver-Burke	Eadie-Hofstee	Hanes-Woolf
Linearized equation	-	$\frac{1}{v} = \frac{K_m}{V_{max}} \left(\frac{1}{[S]} \right) + \frac{1}{V_{max}}$	$v = -K_m \frac{v}{[S]} + V_{max}$	$\frac{[S]}{v} = \frac{1}{V_{max}} [S] + \frac{K_m}{V_{max}}$
x	S	1/S	v/S	S
y	v	1/v	v	S/v
RNase B				
V _{max}	3.5x10 ⁻³	5.09x10 ⁻³	4.6x10 ⁻³	4.6x10 ⁻³
K _m	0.2528	0.497	0.420	0.426
Lactoferrin				
Vmax	4.5x10 ⁻³	7.75x10 ⁻³	6.7x10 ⁻³	6.5x10 ⁻³
K _m	0.4316	1.007	0.828	0.785
Whey				
Vmax	1.9x10 ⁻²	5.2x10 ⁻²	3.7x10 ⁻²	4.3x10 ⁻²
K _m	0.9026	3.18	2.16	2.575

Figure 1. Enzymatic deglycosylation of RNase B by Endo- β -N-acetylglucosaminidase and PNGase F. on 12% SDS-PAGE gel. Lanes 1 :glycosylated RNase B (17kDa) . Lane 2:deglycosylated Rnase B by Endo- β -N-acetylglucosaminidase (47kDa). Lane 3: de glycosylated Rnase B by PNGase F (36kDa).

Figure 2. Reaction curves of EndoBI-1 acting on RNase B, bLF and concentrated whey. The initial substrate concentration ranged from 0.1-0.8 mg/ml for and the enzyme concentration for each experiment was 0.025 mg/ml.

Figure 3. Direct plotting of rate of reaction (v) (mg/mL*min) and substrate concentration $[S]$ (mg/ml).

Figure 4. Lineweaver-Burke ($1/[S]$ (mL/mg) vs $1/v$ (mL*min/mg)), Hanes-Woolf ($[S]$ (mg/mL) vs s/v (min)) and Eadie-Hofstee ($v/[S]$ (min^{-1}) vs v (mg/mL*min)) linearized plotting techniques for the estimation of kinetic parameters of EndoBI-1 on RNase B, bLF and concentrated whey.

Figure 5. Deconvoluted tandem spectrum of high mannose *N*-glycans 5Hex-1HexNAc from RNase B. This glycan corresponded to m/z 1032.36 with $z = +1$. Green circles and blue squares represent mannose and HexNAc residues, respectively.

Figure 6. Extracted compound chromatograms (ECCs) of *N*-glycans from bovine lactoferrin (A) and bovine colostrum whey concentrate (B). The glycan types are differentiated by color: neutral glycans are purple and sialylated glycans are pink. Green circles, yellow circles, blue squares, red triangles, purple diamonds and gray diamonds represent mannose, galactose, HexNAc, fucose, NeuAc and NeuGc residues, respectively.